R236
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 81
- sex
- Male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AUR-AER7-TTM4-A-1-1-R-A742-41 | — | E | 0.921 |
| 2 | SRR9879289 | — | cohortSQ1 | 0.884 |
| 3 | MNG1237 | — | — | 0.882 |
| 4 | TCGA-GM-A3XN-01A-12R-A22U-07 | — | A | 0.875 |
| 5 | R37 | — | — | 0.871 |
| 6 | 69d9a82b-5c37-45bd-a1cf-ffe1392e84fc | — | — | 0.867 |
| 7 | SRR493947 | — | cohortA1 | 0.864 |
| 8 | R24 | — | — | 0.863 |
| 9 | MNG110 | — | — | 0.862 |
| 10 | R89 | — | — | 0.862 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.350 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.330 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.320 | Inavolisib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.280 | Inavolisib | — uncovered |
| COAGULATION | 0.260 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.260 | Inavolisib | — uncovered |
| HYPOXIA | 0.260 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.240 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.210 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.190 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.170 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.160 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.160 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.150 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.120 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.100 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.080 | Idelalisib | — uncovered |